X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dishman Pharma Quarterly Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Dishman Pharma Quarterly Results   (DHPH)

Here are the latest quarterly results of Dishman Pharma. For more details, see the Dishman Pharma financial fact sheet and Dishman Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

Excel Export | Annual Financial Info | Result Scoreboard

Dishman Pharma Quarterly Results

No. of Mths
Qtr. Ending
3
Jun-15
*
3
Sep-15
*
3
Dec-15
*
3
Mar-16
*
3
Jun-16
*
3
Sep-16
*
3
Dec-16
*
3
Mar-17
*
8-Qtr Chart
Click to enlarge
Net Sales Rs m4,0053,8123,8874,2213,7544,3663,6215,342 
Other income Rs m417617130707715538 
Turnover Rs m4,0473,8883,9044,3513,8244,4423,7765,380 
Expenses Rs m2,9612,8972,7873,1752,7323,2082,6643,875 
Gross profit Rs m1,0449151,1001,0461,0221,1589531,462 
Depreciation Rs m259261271299285309293570 
Interest Rs m319236185205225189134101 
Profit before tax Rs m507494661672583736682829 
Tax Rs m130129191174127190175401 
Profit after tax Rs m378365469498455547507428 
Gross profit margin %26.124.028.324.827.226.526.327.4 
Effective tax rate %25.626.129.025.821.925.825.748.4 
Net profit margin %9.49.612.111.812.112.514.08.0 
Diluted EPS Rs 2.3 2.3 2.9 3.1 2.8 3.4 3.1 2.7  
Diluted EPS (TTM) Rs 8.3 8.5 9.9 10.6 11.1 12.2 12.4 12.0  
 Subscriber Feature                  
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster

More Pharmaceuticals Company Quarterly Results:   VENUS REMEDIES  SUVEN LIFE  NOVARTIS  ALEMBIC LTD  SUN PHARMA  

Compare DISHMAN PHARMA With:   VENUS REMEDIES  SUVEN LIFE  NOVARTIS  ALEMBIC LTD  SUN PHARMA  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Energy and Metal Stocks Witness Buying(Closing)

Indian share markets continued their momentum during closing hours of trade and ended the day at their fresh record high levels.

Views on news

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

Eris Lifesciences Limited (IPO)

Jun 15, 2017

Exposure to high margin specialty products offers promising growth prospects.

Laurus Labs Ltd (IPO)

Dec 6, 2016

Equitymaster analyses Initial Public Offering (IPO) of Laurus Labs, one of the leading supplier of APIs for ARVs and Hepatitis C.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS